Heska Co. (NASDAQ:HSKA) Expected to Announce Quarterly Sales of $67.34 Million

Equities analysts forecast that Heska Co. (NASDAQ:HSKAGet Rating) will announce $67.34 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Heska’s earnings, with the lowest sales estimate coming in at $65.85 million and the highest estimate coming in at $69.89 million. Heska posted sales of $60.50 million during the same quarter last year, which would indicate a positive year over year growth rate of 11.3%. The company is scheduled to report its next quarterly earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Heska will report full-year sales of $290.90 million for the current financial year, with estimates ranging from $288.00 million to $293.81 million. For the next fiscal year, analysts expect that the company will report sales of $321.21 million, with estimates ranging from $315.60 million to $331.42 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Heska.

Heska (NASDAQ:HSKAGet Rating) last released its quarterly earnings results on Monday, February 28th. The medical research company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). The firm had revenue of $68.10 million during the quarter, compared to analyst estimates of $66.03 million. During the same period in the prior year, the company posted $0.46 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis.

A number of analysts have recently commented on HSKA shares. Morgan Stanley cut their target price on Heska from $190.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 1st. Alliance Global Partners reduced their price objective on shares of Heska from $310.00 to $240.00 in a research note on Wednesday, March 2nd. TheStreet cut Heska from a “c-” rating to a “d+” rating in a report on Friday, February 11th. Piper Sandler cut their price target on Heska from $210.00 to $190.00 and set an “overweight” rating for the company in a report on Thursday, March 17th. Finally, StockNews.com started coverage on Heska in a research report on Thursday, March 31st. They issued a “hold” rating for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Heska presently has an average rating of “Hold” and an average price target of $235.67.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC lifted its position in shares of Heska by 2.0% during the 1st quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock valued at $38,616,000 after acquiring an additional 8,870 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of Heska during the third quarter worth $2,564,000. Texas Permanent School Fund raised its holdings in shares of Heska by 6.7% during the third quarter. Texas Permanent School Fund now owns 7,874 shares of the medical research company’s stock worth $2,036,000 after acquiring an additional 493 shares in the last quarter. Amalgamated Bank increased its position in Heska by 4.2% during the third quarter. Amalgamated Bank now owns 5,444 shares of the medical research company’s stock worth $1,407,000 after buying an additional 221 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Heska by 565.8% during the third quarter. SG Americas Securities LLC now owns 3,196 shares of the medical research company’s stock worth $826,000 after buying an additional 2,716 shares during the last quarter. 94.47% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:HSKA opened at $127.16 on Friday. The firm has a market cap of $1.37 billion, a PE ratio of -1,156.00 and a beta of 1.59. The stock has a fifty day moving average price of $139.78 and a 200 day moving average price of $164.51. Heska has a 12-month low of $119.63 and a 12-month high of $275.94. The company has a current ratio of 7.27, a quick ratio of 6.15 and a debt-to-equity ratio of 0.23.

About Heska (Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.

Recommended Stories

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.